


A GENERAL APPROACH TO TRANS-CARBAPENEM ANTIBIOTICS.
 ENANTIOSELECTIVE SYNTHESIS OF KEY INTERMEDIATES FOR
 (+)-PS-5, (+)-PS-6, and (+)-THIENAMYCIN

Kazuo Okano, Toshio Izawa, and Masaji Ohno*
 Faculty of Pharmaceutical Sciences, University of Tokyo
 Bunkyo-ku, Hongo, Tokyo 113, Japan

Summary: (S)-4-[(Methoxycarbonyl)methyl]-2-azetidinone prepared by chemico-enzymatic approach has been efficiently converted to key intermediates for the synthesis of natural trans-carbapenem antibiotics, (+)-PS-5, (+)-PS-6, and (+)-thienamycin.

The control of absolute stereochemistry is indeed a central problem in the synthesis of biologically significant enantiomers of natural products. An efficient access to chirality is the enantioselective generation of an asymmetric center from a prochiral starting material by introduction of an enzymatic step. We wish to report here a general approach to the enantioselective synthesis of trans-carbapenem antibiotics, (+)-PS-5, (+)-PS-6 and (+)-thienamycin, through (S)-3-amino-4-methoxycarbonylbutyric acid enzymatically generated. As shown in the general strategy of Scheme I, we noticed that the synthetic problem for the carbapenem antibiotics¹ can be extremely simplified by considering a symmetric factor within the carbapenem nucleus, and have already demonstrated that the prochiral (symmetric) dimethyl 3-benzyloxy-


Scheme I




carbonylaminoglutarate (A, R=Me) was asymmetrically hydrolyzed with pig liver esterase and the resulted chiral half-ester B was cyclized to β -lactam C with $\text{Ph}_3\text{P-PySSPy-CH}_3\text{CN}$ system^{2,3}. The chiral half-ester B (R=Me) is now easily available in quantity by use of the enzymes of microbial origin⁴ (quantitative yield and 98% ee before recrystallization) and the chiral β -lactam C (R=Me) was more efficiently prepared in a large scale by improved procedures^{3,4} (about 90% yield). Thus, (S)-4-[(methoxycarbonyl)methyl]-2-azetidinone (**2**) was subjected to reduction with LiAlH_4 in THF after protection with $t\text{-Bu(Me)}_2\text{SiCl}$ and Et_3N in DMF (0°C, 1h→25°C, 15min) to afford 4-hydroxyethyl derivative **3a** [$[\alpha]_D^{25}$ -52.90 (c 1.98, CHCl_3)]. The hydroxyl group of **3a** was further protected by silylation with $t\text{-Bu(Me)}_2\text{SiCl}$ and Et_3N to afford **3b**, [$[\alpha]_D^{25}$ -49.24 (c 1.98, CHCl_3)], in 97% overall yields from **2**. The protected β -lactam **3b** was also obtained by reduction of **2** with $\text{NaBH}_4\text{-LiCl}$ in DME followed by simultaneous silylation (72% overall yields from **2**). Stereocontrolled introduction of ethyl, isopropyl and acetyl groups at the 3-position of 2-azetidinone **3b** was achieved through the enolate anion (C→D). Addition of ethyl iodide (3.7eq) (-20°C, 3h) to a THF solution containing enolate anion of **3b** generated with LDA (1.2eq) and HMPA (1.9eq) afforded thermodynamically favored *trans*- β -lactam **4** in 92% yield after column chromatography on SiO_2 [hexane:ether=5:1; **4a**, [$\alpha]_D^{25}$ -39.59° (c 2.92, CHCl_3)]. Selective removal of the protective group of the hydroxyl function with N-HCl in MeOH (25°C, 1h) followed by Jones oxidation and removal of the N-silyl group with N-HCl in MeOH (25°C, 4h) afforded **5a** in 50% yield after column chromatography on SiO_2 [$\text{CHCl}_3\text{:CH}_3\text{COCH}_3=3:1$; **5a**, [$\alpha]_D^{25}$ +48.98° (c 1.14, CHCl_3)]. Incorporation of *i*-propyl group also occurred in a stereocontrolled manner by the similar reaction of **3b** and *i*-PrI to afford **4b** in 86% yield, [$\alpha]_D^{20}$ -67.53° (c 2.29, CHCl_3). Aldol condensation of **3b** with acetaldehyde (LDA in THF, -78°C) afforded a mixture of the expected aldol products in a nonstereoselective manner, but aldol condensation of **3b** with acetone under the same condition afforded exclusively *trans*- β -lactam **4c** in 96% yield, [$\alpha]_D^{25}$ -35.63° (c 1.0, CHCl_3). Treatment of **4c** with N-HCl in MeOH (0°C, 30min) followed by oxidation with Collin's reagent afforded **5b** in 80% yield. Conversion of **2** to **5a** constitutes a formal enantioselective synthesis of (+)-PS-5 (1; $\text{R}^1=\text{Et}$, $\text{R}^2=\text{Ac}$), since **5a** was already converted to PS-5⁵. The compound **4b** is a key intermediate for the synthesis of (+)-PS-6^{5a} (1, $\text{R}^1=i\text{-Pr}$, $\text{R}^2=\text{Ac}$) and **5b** was efficiently converted to a epicarpitimycin homologue **6b** by employing Merck method^{1b,6} (Scheme II). Next, the two-step acylation-reduction sequence originally developed by Saltzmann et al⁷ was studied for the stereocontrolled introduction of the hydroxyethyl side chain of **1**. Direct acylation of **3b** with N-acetyl-imidazole (2.3eq) (2.3eq of LDA, THF, -78°C, 20min→quenched with NH_4Cl at -78°C) also provided only *trans* acetyl derivative **7** in 81% yield, [$\alpha]_D^{20}$ -24.43° (c 0.87, CHCl_3). Stereoselective reduction of **7** was satisfactorily achieved by treatment of **7** with K-selectride (2.6eq) in Et_2O ^{7b} to afford **8** in 98% yield on the basis of recovered **7**. The 8R/8S (carbapenem numbering) or erythro/threo product ratio of **8** was found to be 10 to 1 on the basis of ¹H-NMR analysis, and **8** was an

inseparable mixture by tlc. However, the mixture was cleanly separated at the next step. The hydroxyl group of **8** was protected with p-nitrobenzyl chloroformate (PNBOCOCl) in the presence of DMAP, and the resulted mixture was subjected to column chromatography on SiO₂ (hexane: Et₂O=1:1) affording the desired erythro product **9** in 71% yield [$R_f=0.14$, $[\alpha]_D^{20} -5.66^\circ$ (c 1.08, CHCl₃)] and the threo isomer in 7% yield [$R_f=0.21$, $[\alpha]_D^{20} -19.43$ (c 1.97, CHCl₃)]. Removal of the silyl groups of **9** (2N-HCl, THF, 25°C, 12h) afforded **10** quantitatively, a known intermediate to **1**, $[\alpha]_D^{20} +0.85$ (c 1.97, CHCl₃). Therefore, conversion of **2** to **10** constitutes a formal enantioselective synthesis of (+)-thienamycin. The key features of the present methodology includes the following: (1) the monocyclic β -lactam **2** prepared by chemicoenzymatic procedure is indeed a versatile intermediate for various trans-carbapenem antibiotics in natural form; (2) the general approach to carbapenem antibiotics developed here is characterized by remarkable simplicity and efficiency.^{9,10,11}

Scheme II



Scheme III



Acknowledgment. This work was financially supported in part by a Grant-in-Aid for Special Project Research (Innovative Studies on Highly Selective Synthesis). We would like to express our thanks to Dr. S. Kobayashi for helpful discussion at the early stage of this study.

Reference and Notes

1. For previous synthesis, see (a) Karady, S.; Amato, J.S.; Reamer, R.A.; Weinstock, L.M. J. Am. Chem. Soc. 1981, 103, 6765. (b) Saltzman, T.N.; Ratcliffe, R.; Christensen, B.G.; Bouffard, F.A. J. Am. Chem. Soc. 1980, 102, 6161. (c) Melillo, D.G.; Shinkai, I.; Liu, T.; Ryan, K.; Slettinger, M. Tetrahedron Lett. 1980, 21, 2783. (d) Kametani, T.; Huang, S.-P.; Nagahara, T.; Yokoyama, S.; Ihara, M. J. Chem. Soc. Perkin I, 1981, 964.
2. Ohno, M.; Kobayashi, S.; Iimori, T.; Wang, Y-F.; Izawa, T. J. Am. Chem. Soc. 1981, 103, 2405.
3. Kobayashi, S.; Iimori, T.; Izawa, T.; Ohno, M.; J. Am. Chem. Soc. 1981, 103, 2406.
4. The details of asymmetric hydrolysis using enzymes of microbial origin and the improved procedures for cyclization will be reported in separated papers.
5. (a) Kametani, T.; Honda, T.; Nakayama, A.; Sakai, Y.; Mochizuki, T.; Fukumoto, K.; J. Chem. Soc. Perkin I, 1981, 2228. (b) Favara, D.; Omodei-Sali, A.; Consonni, P.; Depaoli, A. Tetrahedron Lett. 1982, 23, 3105.
6. The synthetic details of 6b and other trans-carbapenem antibiotics and their antibacterial activity will be reported elsewhere.
7. (a) Saltzman, T.N.; Ratcliffe, R.W.; Christensen, B.G.; Bouffard, F.A. J. Am. Chem. Soc. 1980, 102, 6163. (b) Bouffard, F.A.; Christensen, B.G.; J. Org. Chem. 1981, 46, 2208. (c) Pecquet, F.; d'Angelo, J. Tetrahedron Lett. 1982, 23, 2777.
8. Johnston, D.B.R.; Schmitt, S.M.; Bouffard, F.A.; Christensen, B.G. J. Am. Chem. Soc. 1978, 100, 313.
9. Further investigation of the present approach to carbapenem antibiotics is now in progress in our laboratory and the results will be reported in due course.
10. All materials described here gave MS, IR, and NMR spectra consistent with their structures.
11. For recent synthesis of 1 using chiral templates, see (a) Ikota, N.; Yoshino, O.; Koga, K. Chem. Pharm. Bull. 1982, 30, 1929, (b) Chida, N.; Miyashita, M.; Yoshikoshi, A.; 25th Symposium on the Chemistry of Natural Products, Tokyo, Abstracts, p. 108 (1982).

(Received in Japan 2 October 1982)